Dr. Pradhan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
900 Commonwealth Ave
Boston, MA 02215Phone+1 617-278-8777
Education & Training
Brigham and Women's HospitalFellowship, Cardiovascular Disease, 2002 - 2005
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1996 - 1999
Georgetown University School of MedicineClass of 1996
Certifications & Licensure
MA State Medical License 1999 - 2024
Clinical Trials
- The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes Start of enrollment: 2006 Aug 01
- Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes Start of enrollment: 2010 Sep 01
- Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) Start of enrollment: 2017 Mar 23
Publications & Presentations
PubMed
- 257 citationsPlatelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events.Aileen Healy, Michael D. Pickard, Aruna D. Pradhan, Yunmei Wang, Zhiping Chen
Circulation. 2006-05-16 - 100 citationsSymptomatic Peripheral Arterial Disease in Women Nontraditional Biomarkers of Elevated RiskAruna D. Pradhan, Sanjay Shrivastava, Nancy R. Cook, Nader Rifai, Mark A. Creager
Circulation. 2008-02-12 - 3068 citationsC-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes MellitusAruna D. Pradhan, JoAnn E. Manson, Nader Rifai, Julie E. Buring, Paul M. Ridker
JAMA. 2001-07-18
Journal Articles
- Trial Designs Rationale and Design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) Study☆Marshall Elam, Aruna D Pradhan, William R Hiatt, ScienceDirect
Press Mentions
Pemafibrate Takes a Small Step Forward in Diabetic Foot Ulcers After CVD FlopJuly 15th, 2024- Pemafibrate Reduces Triglycerides, but Not CV Events, in Patients with T2D, HypertriglyceridemiaDecember 23rd, 2022
- Scientists Discover Surprising Effect Cholesterol-Lowering Drug Has on Heart Disease RiskNovember 14th, 2022
- Join now to see all
Grant Support
- Mechanisms Of Statin-Induced DM In Jupiter (Rosuvasatin For CVD Prevention)National Heart, Lung, And Blood Institute2010–2011
- Novel And Traditional Risk Factors For Symptomatic PAD In WomenNational Heart, Lung, And Blood Institute2007–2010
- Novel/Traditional Risk Factors--Symptomatic PAD In WomenNational Heart, Lung, And Blood Institute2006
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
